Tesamorelin [Peptide]

Description

What is Tesamorelin?

Tesamorelin (INN; brand name Egrifta SV) is a synthetic analogue of endogenous human growth hormone-releasing hormone (GHRH) consisting of the complete 44-amino acid human GHRH sequence with the addition of a trans-3-hexenoic acid group covalently linked to the N-terminal tyrosine residue. Tesamorelin was developed by Theratechnologies, Inc. of Canada; it is the only GHRH analogue to achieve FDA approval and the most clinically validated GHRH compound in the GH axis pharmacology research landscape.

The trans-3-hexenoic acid N-terminal modification stabilises tesamorelin against dipeptidyl peptidase-4 (DPP-4) cleavage at the N-terminal Tyr-Ala bond — the primary plasma degradation pathway for endogenous GHRH — while retaining the full receptor binding and GH-stimulating capacity of the native 44-amino acid sequence. Unlike CJC-1295 with DAC (which achieves half-life extension through albumin binding) or semaglutide (fatty acid albumin binding), tesamorelin’s half-life extension relies primarily on protease resistance rather than albumin binding, resulting in a plasma half-life of 26–38 minutes — shorter than DAC-conjugated compounds but substantially longer than endogenous GHRH’s sub-7-minute half-life.

Tesamorelin (Egrifta) received initial FDA approval in November 2010 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy; it was reformulated as Egrifta SV in 2019 with enhanced reconstitution properties. It is indicated specifically for HIV-associated lipodystrophy — a metabolic complication of antiretroviral therapy characterised by visceral fat accumulation, insulin resistance, and dyslipidaemia — and is the only FDA-approved pharmacological treatment for this specific indication. Pooled analysis of Phase 3 clinical trials demonstrated approximately 15.4% reduction in visceral adipose tissue versus placebo at 26 weeks (p<0.001).

Research-grade Tesamorelin from RCDbio is not Egrifta SV, is not the pharmaceutical formulation, and is not approved or intended for any human therapeutic use. It is not a dietary supplement and is not intended for human consumption or self-administration. All RCDbio research compounds are supplied strictly for laboratory and research purposes only.

Chemical Properties

Property	Detail
Product Type	Synthetic Long-Acting GHRH Analogue (trans-3-Hexenoic Acid N-Terminal Modification; Full 44-AA GHRH Sequence)
Product Name	Tesamorelin
Application	Scientific / Research Use Only
CAS Number	218949-48-5 (free base); 901758-09-6 (salt)
Molar Mass	5135.86 g/mol
Chemical Formula	C221H366N72O67S
PubChem CID	16137828
IUPAC Name	Full canonical IUPAC at PubChem CID 16137828; trans-3-hexenoic acid N-terminal modification on the 44-AA human GHRH sequence
Amino Acid Count	44 amino acids; full human GHRH(1-44) sequence; trans-3-hexenoic acid (trans-3-hexenyl group) attached at N-terminal Tyr1
Key Modification	trans-3-hexenoic acid at N-terminal Tyr1: DPP-4 cleavage resistance; retains full GHRHR binding affinity and GH-stimulating capacity
Receptor Target	GHRHR (Growth Hormone-Releasing Hormone Receptor) on anterior pituitary somatotroph cells; Gαs-coupled GPCR; cAMP/PKA pathway
Elimination Half-Life	26–38 minutes (subcutaneous administration; clinical pharmacokinetics)
Bioavailability	≤4% (subcutaneous; clinical PK studies)
FDA Approval Status	Egrifta SV (tesamorelin) — FDA approved November 2010 (Egrifta); reformulated as Egrifta SV 2019; indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Research-grade Tesamorelin from RCDbio is NOT Egrifta SV and is not approved for human use.
Developer	Theratechnologies, Inc., Montreal, Canada
Synonyms	Tesamorelin; TH9507; Egrifta (pharmaceutical); Egrifta SV (pharmaceutical); GHRH(1-44) trans-3-hexenoyl analogue
Physical Form	Lyophilized white powder
Solubility	Soluble in sterile water for injection; reconstituted per product specification
Storage (Lyophilized)	2–8°C (refrigerated, not frozen) per pharmaceutical storage guidance; −20°C for long-term research storage
Storage (Reconstituted)	2–8°C; use within 24 hours per pharmaceutical guidance; avoid freezing reconstituted solution
Purity	≥98% (HPLC verified, independent third-party laboratory analysis)
WADA Status	Tesamorelin is prohibited at all times under S2.2.4 (Growth Hormone Releasing Factors – GHRH analogues) of the 2026 WADA Prohibited List. Verify at GlobalDRO.com. Pharmaceutical Egrifta SV may qualify for a TUE in specific medical contexts; research-grade material is not eligible. Verify at GlobalDRO.com.

How Does Tesamorelin Work?

Tesamorelin binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells with an affinity equivalent to endogenous GHRH — the N-terminal trans-3-hexenoic acid modification protects against DPP-4 cleavage without altering receptor binding geometry.

GHRHR Gαs/cAMP/PKA Pathway

GHRHR is a Gαs-coupled class B GPCR. Tesamorelin binding initiates adenylyl cyclase activation, elevated intracellular cAMP, and downstream PKA activation in somatotroph cells. This cascade stimulates GH1 gene transcription and pulsatile GH granule exocytosis. Tesamorelin stimulates physiologically pulsatile GH release — preserving natural feedback regulation through IGF-1-mediated negative feedback and somatostatin inhibition — rather than producing continuous GH elevation.

GH/IGF-1 Axis Activation and Visceral Fat Metabolism

GH released by tesamorelin stimulates hepatic IGF-1 production. Elevated GH/IGF-1 axis activity promotes lipolysis specifically in visceral adipose tissue through HSL (hormone-sensitive lipase) activation and adipogenesis inhibition — the mechanistic basis for tesamorelin’s visceral fat reduction effects observed in HIV lipodystrophy clinical trials. In a pooled Phase 3 trial analysis, once-daily subcutaneous tesamorelin (2 mg) reduced visceral adipose tissue by ~15.4% versus placebo at 26 weeks.

Cognitive and Neuroprotective Pathway Effects

In older adult populations and subjects with mild cognitive impairment (MCI), tesamorelin has been investigated in clinical trials for cognitive pathway effects. The proposed mechanism involves GH/IGF-1 axis-mediated neurotrophin pathway upregulation and synaptic plasticity support — IGF-1 readily crosses the blood-brain barrier and has established neurotrophic effects on hippocampal and cortical neurons. A randomised controlled trial in older adults demonstrated improvements in executive function and verbal memory following 20 weeks of tesamorelin, supporting research interest in GHRH axis modulation for cognitive pathway studies.

Key Research Findings

In preclinical and clinical research contexts, Tesamorelin has been associated with the following observations:

• Visceral adipose tissue reduction: ~15.4% reduction in VAT versus placebo at 26 weeks in pooled Phase 3 trial analysis (806 HIV lipodystrophy participants); supported FDA approval [Dhindsa et al., 2010].
• Triglyceride reduction: Concurrent reductions in fasting triglycerides observed in clinical trial populations alongside VAT reduction.
• Cognitive improvement: Improvements in executive function and verbal memory following 20 weeks of tesamorelin in a randomised controlled trial in older adults — proposed mechanism via GH/IGF-1 axis-mediated neurotrophin pathway support.
• Pulsatile GH preservation: Tesamorelin stimulates pulsatile GH release, preserving hypothalamic-pituitary feedback regulation — distinguishing it from exogenous GH replacement, which suppresses endogenous pulsatility.
• NASH/liver fat: Clinical trial data demonstrated tesamorelin-associated reduction in hepatic fat in HIV lipodystrophy patients alongside visceral fat reduction.

Clinical findings relate to the pharmaceutical Egrifta SV formulation at defined doses in approved clinical trial protocols. Research-grade Tesamorelin is not this product. These observations do not constitute evidence of safety or efficacy for research-grade material.

What are the Potential Research Applications?

GHRHR Pharmacology Reference Studies As the FDA-approved GHRH analogue, Tesamorelin serves as the primary clinical reference compound for GHRHR pharmacology investigations. Research employs Tesamorelin in cAMP assays, somatotroph GH secretion studies, and GHRHR-GHRP combination experiments as the validated clinical standard.

Visceral Adipose Tissue Biology and Lipodystrophy Research. In rodent lipodystrophy models and isolated adipocyte preparations, Tesamorelin is investigated for GH/IGF-1-mediated visceral fat mobilisation, HSL activation, and adipogenesis pathway modulation. Research examines the mechanistic specificity of GH axis activation for visceral versus subcutaneous fat compartments.

Cognitive Function and GH/IGF-1 Neuroprotection Research. In aged rodent model preparations and clinical populations, Tesamorelin is investigated for IGF-1-mediated neurotrophin pathway activation, hippocampal neuroplasticity, and the relationship between GH axis stimulation and cognitive function markers in ageing and MCI research contexts.

Comparative GHRH Analogue Pharmacology Tesamorelin (FDA-approved, 44 AA, trans-3-hexenoic acid) is employed alongside Sermorelin (29 AA, GRF 1-29, discontinued), Modified GRF 1-29 (29 AA, tetrasubstituted, no DAC), and CJC-1295 with DAC (29 AA, DAC albumin-conjugated) in comparative studies examining how sequence length, N-terminal modification, and albumin-binding strategy determine GH axis stimulation duration and metabolic outcomes.

What are the Potential Side Effects?

Observations from Phase 3 HIV lipodystrophy clinical trials and post-marketing surveillance for pharmaceutical Egrifta SV.

• Injection site reactions (erythema, pruritus, pain, induration) — most frequently reported adverse event in clinical trial populations; typically mild, site-limited
• Fluid retention — oedema, arthralgias, myalgias reported in clinical trial populations; consistent with GH axis pharmacology
• Glucose intolerance — increases in fasting blood glucose and HbA1c reported; contraindicated in active malignancy in the pharmaceutical context
• Pituitary tumour expansion theoretical risk — as with all GHRH analogues; contraindicated in a history of pituitary tumour in the pharmaceutical context
• No human safety data established for research-grade Tesamorelin outside approved clinical trial contexts

Risk & Handling

Handling Precautions

Tesamorelin should only be handled by trained laboratory personnel. Appropriate PPE: nitrile gloves, lab coat, eye protection. Use in a laminar flow cabinet. Avoid aerosol generation.

Exposure Risks

Risk Tier: MODERATE

Tesamorelin is a clinically validated GHRHR agonist with a 26–38 minute half-life and documented effects on the GH/IGF-1 axis and visceral adipose metabolism. Accidental systemic exposure may produce GH axis activation, potential fluid retention, and transient glucose metabolism changes consistent with GH class pharmacology. No human safety data for research-grade material outside clinical study contexts.

Storage

• Lyophilized: 2–8°C preferred (refrigerated); −20°C for long-term research storage; sealed; light-protected
• Reconstituted: 2–8°C; use within 24 hours; do not freeze reconstituted solution
• Avoid repeated freeze-thaw cycles

Frequently Asked Questions

Q: What is Tesamorelin, and how does it differ from other GHRH analogues? A: Tesamorelin (CAS 218949-48-5; MW 5135.86 g/mol) is the only FDA-approved GHRH analogue, based on the full 44-AA human GHRH sequence with a trans-3-hexenoic acid N-terminal modification for DPP-4 resistance. Sermorelin is a 29-AA fragment (GRF 1-29; discontinued from the US market in 2002). Modified GRF 1-29 is a 29-AA tetrasubstituted fragment without albumin binding. CJC-1295 with DAC is a 29-AA tetrasubstituted fragment with covalent albumin binding extending half-life to 5.8–8.1 days. Tesamorelin is the clinically validated full-sequence reference standard; research-grade Tesamorelin from RCDbio is not Egrifta SV and is not intended for human use.

Q: Is Tesamorelin FDA-approved? A: Egrifta SV (tesamorelin) was FDA approved in November 2010 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy; reformulated as Egrifta SV in 2019. Research-grade Tesamorelin from RCDbio is not Egrifta SV and is not approved for any human use.

Q: What is the significance of the trans-3-hexenoic acid modification? A: The trans-3-hexenoic acid group covalently linked to the N-terminal Tyr1 blocks DPP-4 cleavage at the Tyr-Ala N-terminal bond — the primary plasma degradation pathway for endogenous GHRH. This modification extends tesamorelin’s half-life to 26–38 minutes compared to endogenous GHRH’s sub-7-minute half-life, without altering GHRHR binding affinity or GH-stimulating capacity.

Q: What are the key Phase 3 clinical efficacy findings? A: In a pooled analysis of two Phase 3 randomised controlled trials (806 HIV lipodystrophy participants), once-daily tesamorelin 2 mg SC reduced visceral adipose tissue by ~15.4% versus placebo at 26 weeks (p<0.001), with concurrent reductions in fasting triglycerides. These data supported FDA approval for HIV lipodystrophy. Results relate to the pharmaceutical formulation.

Q: How should Tesamorelin be stored? A: Lyophilized Tesamorelin should be stored at 2–8°C (refrigerated) under pharmaceutical storage guidance; long-term research storage at −20°C is acceptable. Reconstituted solution should be stored at 2–8°C and used within 24 hours. Do not freeze the reconstituted solution. Avoid repeated freeze-thaw cycles.

Related Research Compounds

• Sermorelin — Shortest fully functional GHRH fragment (29 AA; GRF 1-29); provides the historical reference compound for comparative GHRH analogue length and modification pharmacokinetic studies.
• Semaglutide — A GLP-1R agonist; employed alongside Tesamorelin in comparative metabolic research examining GH axis versus incretin axis approaches to visceral fat reduction and metabolic pathway modulation.

All products listed are for laboratory and research purposes only.

References

1. Spooner, L. M., & Olin, J. L. (2012). Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. Annals of Pharmacotherapy, 46(2), 240–247. https://pubmed.ncbi.nlm.nih.gov/22237049/
2. Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://pubmed.ncbi.nlm.nih.gov/18057339/
3. Stanley, T. L., Falutz, J., Marsolais, C., Morin, J., Soulban, G., Mamputu, J. C., & Grinspoon, S. K. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases, 54(11), 1642–1651. https://pubmed.ncbi.nlm.nih.gov/22474177/
4. Baker, L. D., Barsness, S. M., Borson, S., Merriam, G. R., Friedman, S. D., Craft, S., & Vitiello, M. V. (2012). Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology, 69(11), 1420–1429. https://pubmed.ncbi.nlm.nih.gov/22910752/

Disclaimer

Tesamorelin is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition. Research-grade Tesamorelin is not Egrifta SV and is not equivalent to or interchangeable with the approved pharmaceutical formulation.

The Food and Drug Administration has approved tesamorelin as Egrifta SV for HIV-associated lipodystrophy. Research-grade Tesamorelin from RCDbio is not this product and is not approved for human use. Researchers must comply with all applicable laws and regulations. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co